Brain cancer trial tests Immune-Boosting drug before surgery
NCT ID NCT02852655
Summary
This early-stage study is testing whether giving the immunotherapy drug pembrolizumab before surgery can boost the immune system's attack on recurrent glioblastoma, a fast-growing brain cancer. The research involves 60 adults whose cancer has returned after initial treatment. Doctors will measure how the drug changes immune cells in the tumor and track whether it helps control the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan-Kettering Cancer
New York, New York, 10065, United States
-
UT, MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
University of California, San Francisco
San Francisco, California, 94143-0372, United States
Conditions
Explore the condition pages connected to this study.